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Summary.-Antibodies to the tumour-specific transplantation type antigen (TSTA)
of a transplanted methylcholanthrene-induced sarcoma (MC-1) in syngeneic rats
were studied using the techniques of indirect membrane immunofluorescence and
mixed haemadsorption with a 5'Cr-labelled indicator cell. After tumour excision,
anti-TSTA antibody was readily measurable in both serum and lymph. In contrast,
the tumour-bearing animal had no measurable anti-TSTA antibody in the serum
but low titres in the lymph. Consequently, we formed the hypothesis that in the
presence of a growing tumour the serum contained antigen-antibody complexes
with antigen in excess.
To test this hypothesis, tumour-bearing serum was examined for the presence
of free antigen and antigen-antibody complexes by 2 different methods. In the first
method, tumour-bearing serum was cross-linked with glutaraldehyde and was
found to absorb specifically the anti-TSTA antibody, indicating free circulating
TSTA. Next, antigen-antibody complexes were split with salt or acid and separated
into a low molecular weight (or " antigen ") fraction (<100,000) and a high molecular
weighit (or "antibody") fraction (>100,000). The low M.W. fraction specifically
inhibited the anti-TSTA antibody when tested by either membrane immuno-
fluorescence or mixed haemadsorption, indicating the presence of antigen from
antigen-antibody complexes in the tumour-bearing circulation. The possible
effect on the host's immune response of circulating free tumour antigen and antigen-
antibody complexes are discussed.
THE existence oftumour-specific trans-
plantation type antigens (TSTAs) in the
membrane of chemically induced sarco-
mata in experimental animals has been
revealed in suitably immunized animals
by immunologically specific resistance to
tumour grafts, and by the presence of
specifically cytotoxic lymphoid cells in
animals (Foley, 1953; Baldwin, 1955;
Old and Boyse, 1964). However, rats
bearing a primary sarcoma are less able
to reject a second inoculum of the same
tumour than after surgical removal of
the tumour (Mikulska, Smith and Alexan-
der, 1966) and this interference with the
immune response by a growing tumour
was attributed by Alexander and Hall
(1969) to the action of TSTAs released
from the tumour on the lymphoid cells
in the draining node. In man, Thomson
et al. (1969) had shown that the carcino-
embryonic antigen produced by colonic
tumours was present in the serum and
Hellstrom and Hellstrom (1970) reported
that the serum, both from patients and
experimental animals with growing tu-
mours, could " block " the killing in vitro
oftumour cells by lymphoid cells. While
this interference by tumour-bearing serum
was ascribed to the presence of " blocking
antibodies " (Hellstrom and Hellstrom,
1970), the results are also consistent with
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pre-emption of the immune response by
circulating TSTAs, and in recent experi-
ments Sjogren et al. (1971) have found
evidence for antibody-antigen complexes
in the " blocking sera " of rats with
virally induced sarcomata.
The present study had its starting
point in the finding that antibodies
directed to the TSTA of chemically
induced rat sarcomata could not be
found in the serum of tumour-bearing
rats, whereas after removal of the tumour
by amputation of the leg, serum anti-
TSTA antibodies could be detected by
membrane immunofluorescence and by
mixed haemadsorption. A similar ob-
servation had been reported earlier with
chemically induced sarcomata in mice
(Pilch and Riggins, 1966; Harder and
McKhann, 1968), and with rat hepato-
mata (Baldwin and Barker, 1967). The
most simple explanation that the anti-
body was absorbed in vivo by the tumour
was eliminated as the principal factor
by experiments (to be published) which
showed that antibody levels in the
thoracic duct lymph were also much
higher after excision of the tumour than
in the tumour-bearing animals. Anti-
body issuing in this lymph would not
have had an opportunity to be absorbed
by a tumour growing in the leg as the
pathway is from the draining nodes into
the thoracic duct and only then into
the blood. Consequently, we set out to
test the hypothesis that antigen is
released by the tumour and combines with
the circulating antibody, and that in
the presence of a growing tumour there
may be an excess of antigen over anti-
body in the serum. The experimental
procedure was to test if anti-TSTA anti-
bodies found in the serum of rats from
which the tumour had been surgically
excised could be absorbed by serum from
rats with a growing tumour. Immuno-
logical specificity of the absorption was
determined by using the sera of rats with
other transplantable sarcomata since the
TSTAs ofchemicallyinduced sarcomata are
individually specific and do not cross-react.
MATERIALS AND METHODS
Animnals and tumnours.-Inbred male
hooded rats were used throughout and their
genetic identity established by skin grafting.
Primary sarcomata were induced by the
intramuscular implantation of pellets of
either 3,4-benzpyrene or methylcholanthrene
(Haddow and Alexander, 1964) and the
tumours were passaged by trocar transplant.
The tumour studied in these experiments
and designated MC-1 was induced with
20-methylcholanthrene and was highly immu-
nogenic and non-cross-reacting by standard
transplantation tests. All tumours were
grown intramuscularly in the hind limb and
surgically excised when 2-3 cm in diameter
at approximately 14-21 days after implanta-
tion. Aftersurgical excision ofMC-1 tumour,
rats were able to resist an intramuscular
challenge of 107 live tumour cells, while in
normal rats 103 cells gave tumours in 100%
of animals. Early generations were stored
at liquid nitrogen temperature and with-
drawn at intervals for passage in syngeneic
hooded rats. Tests were carried out on
tumours from generation 4-15. Other chem-
ically induced tumours were used for com-
parison.
Serum used for study.-Blood was with-
drawn from tumour-bearing animals via the
draining femoral vein, and from the jugular
vein in 14-day post excision, hyperimmune
and normal rats. Antigenic activity of
tumour-bearing serum was also studied in
immunosuppressed animals. Rats were
given 500 rad of total body x-irradiation,
followred by implantation of MC-1 tumour,
and serum was collected from the femoral
vein at 10, 12, 14 and 21 days after tumour
implantation. All procedures were carried
out under ether anaesthesia. The blood
was immediately stored at 40, and after
overnight retraction of the clot the serum
was separated and stored at 20° until
tested.
Syngeneic tumour-inmnune serum to the
MC-1 fibrosarcoma was raised by injecting
viable MC-1 cells intramuscularly and surgic-
ally excising the resulting tumour. The
rats then received 6 injections ofa mechanica-
ally prepared and irradiated (15,000 rad)
MC-1 tumour cell suspension at multiple
sites, including intraperitoneal, over the
course of 3 months. Rats w-ere bled after
the 6th injection and subsequent bleedings
were preceded by an additional immunization.
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Measurement ofantibodyactivity-by adsorp-
tion of sheep red cells to sarcoma cells.-The
technique used was' a modification of the
method of Tachibana, Worst and Klein
(1970) in that the extent of Linking of sheep
erythrocytes (srbc) coated with anti-srbc
serum and anti-globulin serum to tumour
cells treated with membrane-binding anti-
body was not assayed microscopically but
by labelling the srbc with 51Cr and counting
the radioactivity adherent to the cultured
sarcoma cells.
This technique was developed indepen-
dently by one of us (D.M.P.T.) (Evans and
Alexander (1972)), but recently Sundqvist
and Fagraeus (1972) have reported studies
on the modification ofmixed haemadsorption
with a 5'Cr-labelled indicator cell. Rat
anti-srbc serum was prepared by injecting
washed srbc into multiple subcutaneous
sites 3 times at one-week intervals and
bleeding at the 4th week.
Rat immunoglobulins, IgG, IgM and
IgA were obtained from old breeders' serum
as described by Olsen, McCammon and
Yohn (1970). Adult white New Zealand
rabbits were immunized with the purified
gamma globulin emulsified with an equal
volume of complete Freund's adjuvant and
a total of 2 ml was distributed between 6
intramuscular sites. A booster injection
of 2 ml was prepared with incomplete
Freund's adjuvant and administered sub-
cutaneously at the 4th week. The animals
were bled 3 weeks later. In this system
the maximum reactivity of all antiserum
dilutions was found when the srbc were
sensitized with a 1: 200 dilution of anti-srbc
serum, after which rabbit anti-y-globulin
serum diluted 1: 30 was added. This pro-
cedure was similar in operational details to
that of Tachibana et al. (1970). Sensitized
srbc were labelled with 51Cr just before use
by incubating a 25% srbc suspension for
45 min at 370 with 75-125 ,uCi of 51Cr in
2 ml. The erythrocytes were washed 4
times and stored at 40 until used, when one
additional wash was performed.
Suspensions of MC-1 sarcoma cells were
prepared either from solid tumours' using
trypsin and collagenase digestion', or from
tissue culture after release with trypsin.
2 x 105 cells were seeded in 3 cm Falcon
petri dishes and cultured in 3 ml of tissue
culture medium (Fisher, 1958) and 10%
foetal bovine serum buffered with -Hepes.
At 24 hours the medium was renewed and
at 48-96 hours after original plating the
culture medium was removed and the cell
culture incubated for I hour at 370 with the
test serum diluted 1: 4. The cells were
then washed 4 times with buffered growth
medium 199 (supplied by Glaxo Ltd.)-.
Indicator cells were added at 0-510.75%5.rbc
concentration and incubated for 1 hour at
room temperature, and then the cultures
were washed 4 times with' 1: 1 GVB: med-
ium 199 to remove non-adherent erythro-
cytes. The adherent erythrocytes were lysed
by the addition of 1 ml of distilled water and
the released 51Cr was determined by counting
the activity ofthe supernatant i'n an external
gamma counter. The quantity of antibody
bound by the tumour cells was 'expressed
as the mixed haemadsorption index (MHI):'
MHI =
counts per min from- 5"Cr
in cultures treated with
test serum
counts per min from 5'Cr
in cultures treated with
normal serum
A value of the MHI of 1'2 or greater was
considered significant, because controls of
different types never gave a value greater
than' 1,2. All tests were made in trip-
licate.
Membrane immunofluorescence awssay.-
The indirect membrane immunofluorescence
test was performed on viable single-cell
tumour suspensions obtained from 'finely
minced solid tumour with 0-04% trypsin
and 0-04% collagenase in the presence of a
small amount of DNAse. With syngeneic
MC-1 tumour immune serum, bright and
dense speckled staining, approaching con-
fluence, was observed in 95-100%'of MC 1
cells at serum dilutions up to 1: 6. At
dilutions of 1: 10-1: 12, the number of
fluorescing cells had decreased to 80-90%
and discrete staining was observed. The
antiserum was used at this dilution for all
inhibition assays. Normal serum' samples
caused no such fluorescence, even when
undiluted. The fluorescein-conjugated rab-
bit anti-rat-y-globulin was purchased from
Wellcome Reagents and used at 1: 12
dilution. In order to quantitate the results,
fluorescent indices (FI) were calculated from
the degree of membrane staining obtained
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with specific antiserum compared with that
with normal rat serum:
F'I 000 cells stained with test serum % cells stained with normal serum
and a reaction was defined as positive when
the Fl was equal to or greater than 2-5,
again based on extensive studies using
control sera of different kinds.
Absorption of immune serum with crosss-
linked tumour-bearing serum. The sera to
be used for cross-linking and absorption
studies were dialysed in PBS overnight at
40 and buffered to pH 7 by addition of
1P0 mol/l phosphate buffer before cross-
linking with glutaraldehyde into insoluble
gels as described by Avrameas and Ternynck
(1969). In the absorption studies the stand-
ard procedure was to add 0-7 ml of MC-1
immune serum and 3-5 ml of PBS (pH 7.2)
to 4 ml of the cross-linked absorbent gel.
The mixture was stirred gently for one hour
at room temperature and then left overnight
at 40, after which the serum and gel were
separated by centrifugation at 300 g for
5 min. and the supernatant retained. The
gel was then washed 3 times with PBS
and the original supernatant, together with
the supernatants from the washings, was
concentrated to 2 ml by pressure dialysis
using an Amicon apparatus and a PM-10
membrane. When the absorbed immune
serum was tested, the result was considered
significant if the Fl was lowered by 3000 or
more.
Separation of antigen from antigen-antibody
complex in serum from tumour-bearing rats.-
The principle used for separation depended
on another observation that the TSTA has
a molecular weight of approximately 45,000
when obtained by either 3-5 mol/l KCI or
papain digestion (to be published). Conse-
quently, the sera were treated so that antigen-
antibody complexes would be split and
were then passed through an ultrafiltration
procedure (Amicon filter XM/100) which
would retain molecules of mol. wt. of 100,000
or greater, and allow smaller molecules
(i.e. TSTA) to filter through. To split the
antigen-antibody complexes, either high
concentrations of salt or low pHs were used;
40 ml of 2-0 mol/l sodium iodide in 0 005
mol/l Tris buffer at pH 9, or 40 ml of 0-08
mol/l glycine-HCl buffer, pH 3-1. After
adding the sodium iodide or the glycine-HCl
to 2 ml of serum, the mixture was stirred
and filtered for 1 hour at 40 in the Amicon
apparatus with XM/100 membrane. Both
the retained and filtered fractions were then
adjusted to pH 7-4 by the addition of
0 9 mol/l sodium bicarbonate when glycine-
HCI had been used, or they were dialysed
with PBS pH 7-4 through an Amicon filter
PM/10 which retained all molecules greater
than 10,000 mol. wt. if the separation had
been performed with high molar salt solu-
tions. The 2 fractions were then concen-
trated to their original 2 ml by pressure
dialysis (Amicon) and kept at pH 7-4 with
PBS. For convenience, the fraction con-
taining molecules in the range of 10,000 to
100,000 mol. wt. is referred to as the " anti-
gen" fraction, whereas the fraction con-
taining molecules of molecular weight of
greater than 100,000 is referred to as the
" antibody " fraction. The filtrate was then
tested for its capacity to absorb the antibody
activity of the MC-1 tumour-immune serum
by using it to dilute the immune serum to
1: 10 and 1 : 12. Ifthe " antigen " fraction
inhibited the binding of immune serum to
target cells such that the MHI or Fl fell by
3000 or more, the result was considered
significant.
RESULTS
Evidencefor presence ofantibodies to MC-I
TSTAs in serum of immune animnals
In the serum of animals bearing a
MC-1 tumour, no evidence could be
found for the presence of antibody to
the syngeneic tumour cells (Table I)
either by immunofluorescence or by mixed
haemadsorption tests, although the serum
was examined from the time of tuimour
implantation for 21 days.
After surgical removal of the tumour,
however, anti-TSTAs antibodies were
detected in the serum, the highest MHI
or FI being found at 14 days post-
excision. This tumour-immune serum
was specific for MC-1 tumour and did
not cross-react with 6 different chemically
induced tumours. Likewise, serum taken
2 weeks post-excision from 6 different
chemically induced tumours did not cross-
react with the MC-1.
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TABLE I.-Detection of Antibodies to the TSTA of the MCI Sarcoma in the
Sera ofSyngeneic Rats
Origin of sera
Normal rats
Rats with growing MCI tumour.
2 weeks after excision of MCI
Rat hyper-immunized with MCI
2 weeks after excision of tumour
other than MCI
No. of
Dilution different
of serum sera
used tested
1/4 10
1/4 . 10
1/4 10
1/12 8
1/212 . 8
1/4
A high titre MC-1 tumour-immune
serum was raised in the post-excision
animals by repeated immunizations with
irradiated MC-1 tumour cells. This was
specific for the immunizing MO-1 sarcoma
at dilutions of greater than 1: 6, but
at lesser dilutions cross-reactions were
obtained with other chemically induced
sarcomata, as determined by both mixed
haemadsorption and membrane immuno-
fluorescence. With the MO-I tumour-
immune serum, diluted 1 5, and other
No. of sera giving
an MHI of
< 1-3 1-4-1-8 > 1-9
10 0 0
10 0 0
0 0 10
0 0 8.
0 7 1.
No. of sera giving
FI of
<2-4 2-5-5-0 5-1-10-0
10
10
8
0
6
0
0
4
8
. 10 0 0 . 10 0 0
of MO-1 tumour-immune serum was
principally obtained with cross-linked
MO-1 tumour-bearing sera. Out of 15
tumour-bearing sera used for absorption,
12 gave significant lowering of the index.
This reaction was specific in that cross-
linked serum of control normal rats, and
of post-excision rats, produced no signi-
ficant lowering of the index. When sera
from animals bearing tumours other than
the MC-1 were assayed, only one gave
any evidence of absorption of the anti-
TABLE II.-Antibody Activity in Tumour-immune Serum to MC-1
Sarcoma after Absorption with Cross-linked Tumour-bearing Serum
Sera used for absorption
Control (normal rats) .
MCI (tumour-bearing) .
Post-excision MCI sera
Rats bearing other tumours
Irradiated rats with growing MCI .
chemically induced sarcomata as the
target cells, Fl of 2-53-0 were obtained
in comparison to Fl of 13-5 or greater
with MC-1 target cells. Similar results
were found with the mixed haemadsorp-
tion technique. In absorption studies,
MO-1 tumour cells specifically lowered
the Fl and MHI ofMO-1 tumour-immune
serum to values of unity, whereas other
chemically induced tumours lowered the
Fl and MHI of MO-1 tumour-immune
serum by less than 25%.
Absorption ofantibody to TSTA by tumour-
bearing serum
As shown in Table II the absorption
3
No. of different tests
MHI FI
7 6
15 10
6 2
8 4
3 8
* 21-day serum.
TSTA antibody
immune serum.
No. of sera showing
absorption of antibody
MHI Fl
MHI Fl
0
12
0
2
1*
0
7
0
1
2*
in the MO-1 tumour-
Evidence for the presence of antigen-
antibody (Ag-Ab) complexes in tumour-
bearing serum
The ability of tumour-bearing serum
to inhibit MC-1 tumour-immune serum
could be considerably increased by treat-
ing the serum with acid or high molar
salt and then separating this serum into
high and low molecular weight fractions
with Diaflo Membrane XM/100. Table
III shows that the fractions of less than
100,000 mol. wt. (" antigen " fraction),
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TABLE III.-Absorption of Antibody in Hyperimmune Serum by " Antigen " Fraction
Obtained by Dissociating Antibody-Antigen Complex in Sera of Tumour-bearing
Animals
Sera from which Ag fraction
had been obtained
Control
MCI tumour-bearing sera
MCI tumour-bearing sera normal pH
Rats bearing other tumours
MCI tumour-bearing irradiated
whether obtained by treatment of the
tumour-bearing serum with low pH or
high molar salt solutions, were very
effective in neutralizing the capacity of
the tumour-immune serum to cause im-
munofluorescence or mixed cell haemad-
sorption. In contrast, in tumour-bearing
serum not subjected to Ag-Ab splitting
techniques, the separated low mol. wt.
fraction did not lower the FI or MHI.
Also, the high mol. wt. fraction did not
show any antigenic activity, as tested by
ability to inhibit the antibody in the
tumour-immune serum. Table II and
III indicate that for the MC-1 tumours
at least, TSTA is released into the circula-
tion and part of the antigenic activity is
neutralized by a substance of mol. wt.
greater than 100,000, from which it can
be dissociated by lowering the pH or
raising the molarity of the solution.
These data are consistent with the hypo-
thesis that tumour-bearing serum contains
antigen-antibody complexes with antigen
in excess.
Inability to detect circulating TSTA in
serum ofimmunosuppressed tumour-bearing
rats
Since the experiments described in
the previous section have shown that
part of the antigenic activity of the
tumour-bearing serum is blocked by anti-
body, it seemed that one might raise the
antigenic activity of the tumour-bearing
serum by growing tumours in immuno-
suppressed animals. Consequently, rats
No. of different
sera tested by
A
MHI
3
4
2
3
3
No. of fractions which
absorbed antibody
activity as measured by
FI MHI
9 . 0
13 . 3
4 . 0
4 . 1
4 . 1
Fl
0
10
0
1
1
were given 500 rad oftotal body x-irradia-
tion followed by MC-1 tumour implanta-
tion. The sera from these animals after
10-12 days gave no evidence ofcirculating
TSTA. Only at 21 days were any signi-
ficant results obtained (Table II). Table
III shows that even after the sera had
been acidified and an " antigen " fraction
separated, no indication of antigenic
activity could be found. This unex-
pected finding indicates that for the
MC-1 tumour, high levels of circulating
TSTA are not reached with normal
metabolic cell surface turnover and it
would appear that a local immune reac-
tion is necessary before measurable quan-
tities ofantigen are released from tumours
into the circulation.
DISCUSSION
The MC-1 chemically induced fibro-
sarcoma is highly antigenic and it is
possible to produce considerable resistance
of animals to this tumour by immuniza-
tion. The tumour-specific antigen
responsible for this graft resistance,
the TSTA, has been shown to evoke the
production of a specific antibody in the
syngeneic animal, but the antibody acti-
vity in the serum of a tumour-bearing
animal is masked by the release into the
circulation of soluble TSTA which form
antigen-antibody complexes. No evi-
dence has been obtained to indicate that
the serum of tumour-bearing animals
is ever in antibody excess. Our series
of experiments would indicate that the
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release of antigen in quantities measur-
able by our techniques requires an active
immune reaction and this is clearly a
phenomenon that has to be investigated
in more detail.
In man, a colonic tumour-associated
antigen (CEA), has been shown by radio-
immunoassay techniques to be released
into the circulation (Thomson et al.,
1969), and also soluble HL-A antigens
have been demonstrated in human sera
(Charlton and Zmijewski, 1970). Studies
of the metabolism of the surface mem-
brane molecules have shown a con-
tinuous cell surface turnover and release
ofsubstances into the surrounding medium
(Warren and Glick, 1968). Our studies
appear to indicate that the local immune
reactions increase this cell surface turn-
over and subsequent release.
After excision of the tumour, cir-
culating antigen is rapidly cleared and
anti-TSTA antibody levels build up so
that in the 7-14 days post-excision
serum fairly high titres of specific anti-
body can be detected. The presence in
the serum of tumour-bearing animals of
both free antigen and antigen-antibody
complexes may influence the host reaction
directed against the tumour in a number
of ways. The suggestion has already
been made that in the presence of excess
antigen the migration of immunoblasts
from the draining node may be blocked
(Hall and Morris, 1965). Immunoblasts
are, however, only one component in
the cell-mediated response of the host
against the tumour; small memory-type
lymphocytes and macrophages are also
involved. It is possible that the cir-
culating antigen and/or antigen-antibody
complexes may, by directly interacting
with the lymphoid cells or macrophages,
interfere with their capacity to kill the
specific target tumour cell. Vaage (1972)
has shown that host resistance to tumour
cell challenge can be depressed by giving
killed tumour cells during the first week
of tumour challenge. The depression of
host resistance by antigenic tumour tissue
appears to be the result of excess antigen
and not " blocking " antibody. If this
artificially induced antigen excess can
depress in vivo rejection of a tumour
challenge, the demonstration of the pre-
sence of excess circulating TSTA in the
tumour-bearing animal may be inter-
preted as having a similar adverse effect.
In view of our results, the recent report
by Bansal and Sjogren (1971) of sera
with " unblocking " activity in polyoma
virus-induced tumours in rats is of
interest. Here, sera from immune rats
counteracted the blocking effect of sera
from animals with progressively growing
tumours on cell-mediated specific cyto-
toxicity. Moreover, such sera induced
regression of 4 out of 5 transplanted
tumours. The mechanism of the " un-
blocking" is not known but it was
postulated that in vitro competition occ-
urredbetween " blocking " and " unblock-
ing" antibodies on the surface of the
target tumour cell. An alternative hypo-
thesis is that an excess of high affinity
anti-TSTA antibody is achieved which
clears the excess soluble antigen and
reverses the " blocking " induced by this
antigen-antibody complex in the tumour-
bearing serum.
The results of the present investiga-
tion should also raise important questions
of the efficiency of some of the present
immunotherapy programmes in human
cancer. Here, tumour cells may be in-
jected in a situation where there is already
tumour antigen excess, thereby increasing
the antigen load and further suppressing
the immune response. In cancerimmuno-
therapy the removal of excess circulating
antigen by administration of antibody
might allow the host response to be maxi-
mally active in tumour rejection.
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